NASDAQ:ATXS Astria Therapeutics (ATXS) Stock Price, News & Analysis $6.56 -0.36 (-5.20%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.56 0.00 (-0.08%) As of 08/1/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Astria Therapeutics Stock (NASDAQ:ATXS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Astria Therapeutics alerts:Sign Up Key Stats Today's Range$6.52▼$6.8650-Day Range$3.92▼$6.9252-Week Range$3.56▼$12.92Volume233,456 shsAverage Volume229,657 shsMarket Capitalization$370.18 millionP/E RatioN/ADividend YieldN/APrice Target$29.00Consensus RatingBuy Company Overview Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. Read More Astria Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreATXS MarketRank™: Astria Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 554th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingAstria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAstria Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Astria Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.65) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Astria Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Astria Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAstria Therapeutics has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Astria Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.78% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Astria Therapeutics has recently decreased by 3.13%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAstria Therapeutics does not currently pay a dividend.Dividend GrowthAstria Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.78% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Astria Therapeutics has recently decreased by 3.13%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News Sentiment0.82 News SentimentAstria Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Astria Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for ATXS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Astria Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of Astria Therapeutics is held by insiders.Percentage Held by Institutions98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Astria Therapeutics' insider trading history. Receive ATXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATXS Stock News HeadlinesAstria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE PatientsAugust 1 at 4:00 AM | msn.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of "Buy" by BrokeragesAugust 1 at 3:11 AM | americanbankingnews.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. | Brownstone Research (Ad)Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National SummitJuly 7, 2025 | finance.yahoo.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Seeking AlphaJuly 3, 2025 | seekingalpha.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMATXS - Astria Therapeutics Inc Key Metrics - MorningstarJuly 2, 2025 | morningstar.comMAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | businesswire.comSee More Headlines ATXS Stock Analysis - Frequently Asked Questions How have ATXS shares performed this year? Astria Therapeutics' stock was trading at $8.94 at the beginning of 2025. Since then, ATXS stock has decreased by 26.6% and is now trading at $6.56. How were Astria Therapeutics' earnings last quarter? Astria Therapeutics, Inc. (NASDAQ:ATXS) announced its quarterly earnings data on Tuesday, May, 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.10. When did Astria Therapeutics' stock split? Astria Therapeutics shares reverse split on Friday, August 20th 2021.The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. Who are Astria Therapeutics' major shareholders? Astria Therapeutics' top institutional shareholders include Farther Finance Advisors LLC (0.01%). Insiders that own company stock include Perceptive Advisors Llc and Christopher Morabito. View institutional ownership trends. How do I buy shares of Astria Therapeutics? Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Astria Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Astria Therapeutics investors own include CRISPR Therapeutics (CRSP), Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AU Optronics (AUOTY). Company Calendar Last Earnings5/13/2025Today8/01/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATXS CIK1454789 Webwww.catabasis.com Phone(617) 349-1971Fax617-273-2637Employees30Year Founded2008Price Target and Rating Average Price Target for Astria Therapeutics$29.00 High Price Target$47.00 Low Price Target$16.00 Potential Upside/Downside+342.1%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$94.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.18% Return on Assets-31.26% Debt Debt-to-Equity RatioN/A Current Ratio17.39 Quick Ratio17.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book1.65Miscellaneous Outstanding Shares56,430,000Free Float53,894,000Market Cap$370.18 million OptionableOptionable Beta0.47 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:ATXS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.